<DOC>
	<DOCNO>NCT00611351</DOCNO>
	<brief_summary>RATIONALE : Giving chemotherapy donor bone marrow transplant peripheral stem cell transplant help stop growth cancer cell help stop patient 's immune system reject donor 's stem cell . When certain stem cell donor infused patient may help patient 's bone marrow make stem cell , red blood cell , white blood cell , platelet . Sometimes transplanted cell donor make immune response body 's normal cell . Giving tacrolimus mycophenolate mofetil transplant may stop happen . PURPOSE : This phase II trial study well give busulfan together cyclophosphamide antithymocyte globulin follow donor stem cell transplant work treat patient hematologic cancer .</brief_summary>
	<brief_title>Busulfan , Cyclophosphamide , Antithymocyte Globulin Followed Donor Stem Cell Transplant Treating Patients With Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine incidence grade II-IV acute graft-versus-host disease patient hematologic cancer disease treat myeloablative conditioning regimen comprise target ( steady-state concentration 800-1,000 ng/mL ) busulfan , cyclophosphamide , anti-thymocyte globulin follow match unrelated donor allogeneic hematopoietic stem cell transplantation . - To determine day +100 transplantation-related mortality patient . Secondary - To determine effect cyclophosphamide pharmacokinetic parameter day +100 transplantation-related mortality patient . - To determine ability low-dose anti-thymocyte globulin administer day +5 induce activation-induced cell death activate donor lymphocyte . - To determine incidence chronic graft-versus-host disease patient treat regimen . - To determine event-free overall survival patient treat regimen . - To evaluate pharmacogenomic association genetic polymorphism drug disposition enzymes pharmacokinetics busulfan cyclophosphamide . OUTLINE : - Myeloablative conditioning regimen : Patients receive busulfan IV 2 hour day -8 -5 ; cyclophosphamide IV 4 hour day -3 -2 ; anti-thymocyte globulin IV 6 hour day -3 4 hour day -2 , -1 , 5 . - Allogeneic hematopoietic stem cell transplantation : Patients undergo allogeneic bone marrow peripheral blood stem cell infusion day 0 . - Graft-versus-host-disease prophylaxis : Patients receive tacrolimus IV continuously orally day 6 to150 , follow even taper day 180 absence graft-versus-host-disease . Patients also receive mycophenolate mofetil IV orally begin day 6 continue day 28 . Patients undergo blood collection periodically study pharmacokinetic , pharmacogenomic , translational study . Genomic DNA extract blood sample analyze polymerase chain reaction genetic polymorphism cyclophosphamide/busulfan disposition enzyme . Activated donor lymphocyte assess use flow cytometry measure activation-induced cell death , reflect apoptosis activate T cell . Chimerism around day 100 also assess use fluorescence situ hybridization analysis DNA fingerprinting . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Pathologically confirm diagnosis 1 following : Acute myeloid leukemia Acute lymphocytic leukemia Chronic myelogenous leukemia beyond first chronic phase ( i.e. , 2nd chronic phase , accelerated phase , blast crisis ) Multiple myeloma Myelodysplastic syndrome Malignant lymphoma Myelofibrosis Requirement myeloablative conditioning regimen confirm attend physician Available donor must meet following criterion : HLA phenotypically identical unrelated donor low , intermediate , high resolution HLA class I antigens , high resolution HLA class II antigens Matched A , B , DRβ1 loci Single HLAA HLAB antigen mismatch allow Meets National Marrow Donor Program foreign registry criterion allogeneic bone marrow/stem cell donor Peripheral blood stem cell preferred product study bone marrow allow PATIENT CHARACTERISTICS : Karnofsky performance status 70100 % DLCO ≥ 50 % predict LVEF ≥ 45 % Serum creatinine ≤ 1.5 mg/dL creatinine clearance ≥ 65 mL/min Serum total bilirubin ≤ 2.0 mg/dL No active uncontrolled infection Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No HIV infection No chronic active hepatitis B C evidence cirrhosis liver biopsy PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>graft versus host disease</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>untreated adult acute lymphoblastic leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>myelodysplastic/myeloproliferative disease , unclassifiable</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>secondary myelofibrosis</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>recurrent adult Burkitt lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
	<keyword>recurrent adult lymphoblastic lymphoma</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage IV adult T-cell leukemia/lymphoma</keyword>
	<keyword>stage III adult Burkitt lymphoma</keyword>
	<keyword>stage IV adult Burkitt lymphoma</keyword>
	<keyword>stage III adult diffuse large cell lymphoma</keyword>
	<keyword>stage IV adult diffuse large cell lymphoma</keyword>
	<keyword>stage III adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage IV adult diffuse mixed cell lymphoma</keyword>
	<keyword>stage III adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
	<keyword>stage III adult lymphoblastic lymphoma</keyword>
	<keyword>stage IV adult lymphoblastic lymphoma</keyword>
	<keyword>stage III grade 1 follicular lymphoma</keyword>
	<keyword>stage III grade 2 follicular lymphoma</keyword>
	<keyword>stage III grade 3 follicular lymphoma</keyword>
	<keyword>stage IV grade 1 follicular lymphoma</keyword>
	<keyword>stage IV grade 2 follicular lymphoma</keyword>
	<keyword>stage IV grade 3 follicular lymphoma</keyword>
	<keyword>stage III mantle cell lymphoma</keyword>
	<keyword>stage IV mantle cell lymphoma</keyword>
	<keyword>stage III marginal zone lymphoma</keyword>
	<keyword>stage IV marginal zone lymphoma</keyword>
	<keyword>stage III small lymphocytic lymphoma</keyword>
	<keyword>stage IV small lymphocytic lymphoma</keyword>
	<keyword>stage III adult diffuse small cleave cell lymphoma</keyword>
	<keyword>stage IV adult diffuse small cleave cell lymphoma</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>atypical chronic myeloid leukemia</keyword>
	<keyword>noncontiguous stage II adult Burkitt lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse mixed cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult diffuse small cleave cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult immunoblastic large cell lymphoma</keyword>
	<keyword>noncontiguous stage II adult lymphoblastic lymphoma</keyword>
	<keyword>noncontiguous stage II grade 1 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 2 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II grade 3 follicular lymphoma</keyword>
	<keyword>noncontiguous stage II mantle cell lymphoma</keyword>
	<keyword>noncontiguous stage II marginal zone lymphoma</keyword>
	<keyword>noncontiguous stage II small lymphocytic lymphoma</keyword>
	<keyword>refractory hairy cell leukemia</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
</DOC>